文献速递精神分裂症与精神病性障碍

精神分裂症的抗精神病药增效与单药治疗:系统综述、荟萃分析与元回归分析

Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.
PubMed 文献 · World Psychiatry · 2017-01-01

该系统综述与随机效应荟萃分析比较了精神分裂症中第二种抗精神病药增效与持续单药治疗的疗效与安全性。增效治疗在总体症状改善上优于单药,但优势仅见于开放标签和低质量试验;双盲高质量试验中无显著差异。阴性症状改善仅见于阿立哌唑增效研究。

要点

  • 抗精神病药增效在总体症状改善上优于单药,但仅在开放标签和低质量试验中显著,双盲高质量试验无差异。
  • 研究定义的应答率在增效与单药间无显著差异,双盲高质量研究中同样不显著。
  • 阴性症状改善仅见于阿立哌唑增效研究,其他增效药物未见此优势。

核心结论

  • 抗精神病药增效治疗在精神分裂症中缺乏双盲高质量证据支持其疗效,仅阿立哌唑增效对阴性症状改善有证据。

研究设计与样本

  • 系统文献检索与随机效应荟萃分析,纳入比较第二种抗精神病药增效与持续单药治疗的随机试验。
  • 共纳入16项研究(N=694)分析总体症状改善,14项研究(N=938)分析研究定义的应答,18项研究(N=931)分析阴性症状。

主要发现

  • 抗精神病药增效在总体症状改善上优于单药(16项研究,N=694,SMD=-0.53,95% CI:-0.87至-0.19,p=0.002)。
  • 增效优势仅见于开放标签试验(p<0.001)和低质量试验(p<0.001),双盲试验(p=0.120)和高质量试验(p=0.226)中不显著。
  • 研究定义的应答率在增效与单药间无显著差异(14项研究,N=938,RR=1.19,95% CI:0.99至1.42,p=0.061),双盲和高质量研究中均不显著(p=0.990)。
  • 阴性症状改善更见于增效治疗(18项研究,N=931,SMD=-0.38,95% CI:-0.63至-0.13,p<0.003),但仅见于阿立哌唑增效研究(8项研究,N=532,SMD=-0.41,95% CI:-0.79至-0.03,p=0.036)。
  • D2拮抗剂增效与更少失眠相关(p=0.028)但更多催乳素升高(p=0.015),阿立哌唑增效与催乳素水平降低(p<0.001)和体重降低(p=0.030)相关。

关键数值与推荐

  • 抗精神病药增效在总体症状改善上优于单药(SMD=-0.53,95% CI:-0.87至-0.19,p=0.002),但仅限开放标签和低质量试验。
  • 研究定义的应答率在增效与单药间无显著差异(RR=1.19,95% CI:0.99至1.42,p=0.061)。
  • 阴性症状改善仅见于阿立哌唑增效研究(SMD=-0.41,95% CI:-0.79至-0.03,p=0.036)。

临床怎么用

  • 临床实践中常见的抗精神病药增效策略缺乏双盲高质量证据支持其疗效,应谨慎使用。
  • 阿立哌唑增效可能对阴性症状改善有益,但需结合个体情况评估。
  • 增效治疗时需注意不良反应差异,如D2拮抗剂增效可能升高催乳素,阿立哌唑增效可能降低催乳素和体重。

局限性

  • 增效治疗的疗效优势主要见于开放标签和低质量试验,双盲高质量试验中未证实。
  • 阴性症状改善仅见于阿立哌唑增效研究,其他增效药物缺乏证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and costly with unclear evidence for its efficacy and safety. We conducted a systematic literature search and a random effects meta-analysis of randomized trials comparing augmentation with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia. Co-primary outcomes were total symptom reduction and study-defined response. Antipsychotic augmentation was superior to monotherapy regarding total symptom reduction (16 studies, N=694, standardized mean difference, SMD=-0.53, 95% CI: -0.87 to -0.19, p=0.002). However, superiority was only apparent in open-label and low-quality trials (both p<0.001), but not in double-blind and high-quality ones (p=0.120 and 0.226, respectively). Study-defined response was similar between antipsychotic augmentation and monotherapy (14 studies, N=938, risk ratio = 1.19, 95% CI: 0.99 to 1.42, p=0.061), being clearly non-significant in double-blind and high-quality studies (both p=0.990). Findings were replicated in clozapine and non-clozapine augmentation studies. No differences emerged regarding all-cause/specific-cause discontinuation, global clinical impression, as well as positive, general and depressive symptoms. Negative symptoms improved more with augmentation treatment (18 studies, N=931, SMD=-0.38, 95% CI: -0.63 to -0.13, p<0.003), but only in studies augmenting with aripiprazole (8 studies, N=532, SMD=-0.41, 95% CI: -0.79 to -0.03, p=0.036). Few adverse effect differences emerged: D2 antagonist augmentation was associated with less insomnia (p=0.028), but more prolactin elevation (p=0.015), while aripiprazole augmentation was associated with reduced prolactin levels (p<0.001) and body weight (p=0.030). These data suggest that the common practice of antipsychotic augmentation in schizophrenia lacks double-blind/high-quality evidence for efficacy, except for negative symptom reduction with aripiprazole augmentation.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Galling B, Roldán A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017. PMID: 28127934. doi:10.1002/wps.20387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。